[Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study].
BACKGROUND
The EOLE cohort aimed to describe, in routine clinical practice, the characteristics and management of patients receiving bevacizumab in combination with first-line metastatic chemotherapy for advanced metastatic or recurrent non squamous non-small cell lung cancer (nsNSCLC), as well as its efficacy and safety.


METHODS
A total of 423 patients were enrolled in this prospective, national, multicenter study. Data were collected every 3 months over an 18-month period.


RESULTS
Amongst the 407 patients analyzed (mean age 60±10 years, male 68%, ECOG-PS≤1 88%, smokers or former smokers 87%, cardiovascular comorbidities 40%), all except for 2 patients received bevacizumab (7.5 or 15mg/kg/3 weeks in 99% of patients) in combination with doublet chemotherapy. A total of 160 (60%) patients who completed induction received bevacizumab maintenance therapy. Median progression-free survival was 6.9 months (95% CI=[6.0-7.5]). Median overall survival (12.8 months [10.4-14.7]) was longer in patients with ECOG-PS≤1 (14.4 months [12.3-15.9] versus 4.9 months [3.4-8.3] if ECOG-PS=2). A total of 131 (32%) patients experienced at least one serious adverse event (SAE), and 51 (12%) at least one bevacizumab-related SAE.


CONCLUSIONS
EOLE confirms the efficacy and safety of bevacizumab in aNSCLC patients, in current medical practice.
Service de pneumologie, centre hospitalier intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France. Electronic address: christos.chouaid@chicreteil.fr.
C
C
Chouaid
Pneumologie, hôpital Nord-Ouest, 69655 Villefranche-sur-Saône, France.
L
L
Falchero
Médecine oncologique, centre Paul-Strauss, 67000 Strasbourg, France.
R
R
Schott
EA 3181 et oncologie, université de Franche-Comté, centre hospitalier régional universitaire Jean-Minjoz, 25030 Besançon, France.
F
F
Bonnetain
Roche, 30, cours de l'Île-Seguin, 92100 Boulogne-Billancourt, France.
N
N
Taguieva-Pioger
Service d'oncologie, institut de cancérologie de l'Ouest René-Gauducheau, 44805 Nantes-Saint-Herblain, France.
J
J
Bennouna
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
Bevacizumab; Carcinome bronchique non à petites cellules; Non-small-cell lung carcinoma; Observational study; Progression-free survival; Survie sans progression; Étude observationnelle